Immunotherapy Advances

🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it.

Read: vist.ly/4tzga

🔬 New open‑access review explores tumour‑associated macrophages (TAMs): their role in tumour progression, metastasis, therapy resistance, and the ongoing challenge of identifying reliable TAM surface markers for immunotherapy development.

🔗 https://bit.ly/4i95qnm

🚨 Call for Papers! “CD40 turns 40: Four Decades of ‘Forty’-fying Immunotherapy.”

We invite submissions on CD40/CD154 biology & therapeutic innovation across cancer, autoimmunity, transplantation & allergy.

📝 Deadline: March 2026
📩 More info: journals@immunology.org

🧬 Spatial profiling of metastatic dMMR colorectal cancer shows why some lesions respond to PD‑1 therapy: responsive sites have strong cytotoxic/IFN‑γ activity, while resistant ones show immunosuppressive macrophage programs.

🔗 https://bit.ly/4qSV3bL

#Immunotherapy #CancerResearch

Metabolic dysregulation plays a key role in Behçet’s disease. Elevated glucose & TAG levels drive Th1 differentiation, CD8⁺ T cell activation and B cell antibody production, contributing to immune dysfunction.

Read the study: https://bit.ly/44HA2t9

📢 Special Collection CD40 turns 40: Four Decades of ‘Forty’-fying Immunotherapy🧬

Exploring 40 years of CD40/CD154 biology, therapeutics, and future directions across cancer, autoimmunity, transplantation & allergy.

Submissions open until March 2026: https://bit.ly/4rMo7lY

New in Immunotherapy Advances: CD137 aptamer–shRNA chimeras show promise for targeting intratumoral Tregs. This approach downregulates key genes like EzH2 & Nrp1 in CD137⁺ Tregs and malignant cells, offering a potential new route for tumour immunotherapy.

🔗 https://bit.ly/4ad5S3o

This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back.

Read the open access review here: https://bit.ly/4291Ipg

#CancerResearch #Immunotherapy #BiTEs

This #WorldCancerDay, explore how boosting natural killer (NK) cell activity, from CAR‑NK therapies to NK‑cell engagers and checkpoint strategies, could strengthen our fight against cancer.

Read the open access review: https://bit.ly/4j8dKEW

#Immunotherapy #NKcells

🎗️ Ahead of #WorldCancerDay, check out this review by Shania Makker, Charlotte Galley & Clare L Bennett exploring how advances in immunology and mRNA platforms are reshaping the future of therapeutic cancer vaccines.

Read the article: https://bit.ly/4cefxGm

A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs.

Read the open access article: https://bit.ly/3HnCGdN

📢 Call for papers!

Immunotherapy Advances invites submissions for our Special Collection on Neuroimmunology and Immunotherapy, guest edited by Marianne Boes & Majid Ghareghanim.

Deadline: March 2026.

Submit now: https://bit.ly/45mr1m8

🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors.

Read the open access article: https://bit.ly/3Z8hDBW

#Immunotherapy #CellTherapy

✨ Our 2025 must‑read articles are now live!

Explore the most‑viewed and most‑cited immunotherapy papers from the past year

Discover them here: https://bit.ly/45ELeXc

#Immunotherapy

Low MHC‑I expression remains a major barrier to effective tumour immunotherapy, especially in paediatric cancers.

This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.

📄 https://bit.ly/45vtfmp

Special Collection: Neuroimmunology and immunotherapy

Support @imtadvances.bsky.social in advancing immunotherapies for neurodegenerative & CNS immune-mediated diseases.

We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp

#ImmunoSky #Immunotherapy

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders.

Read here📄 https://bit.ly/4pw1rVL

🚀 Submit your work to the Neuroimmunology & Immunotherapy Special Collection

Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.

Deadline: March 2026.

Learn more: https://bit.ly/4psT5hG

Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy.

This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.

📄 https://bit.ly/3SVZsMC

Happy holidays from all of us! ❄️✨

Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!

Natural killer cells are gaining momentum in cancer immunotherapy. This open-access review in Immunotherapy Advances explores how CAR-NK cells, NK engagers, cytokines and checkpoint inhibitors are being harnessed to boost anti-tumour immunity.

🔗 https://bit.ly/4j8dKEW

🎧 ITA Wrapped!

A standout year for Immunotherapy Advances!

Thank you to our authors, reviewers and readers for helping ITA grow its reach and impact in 2025.

person reading posters at BSI congress

Congratulations to the winners of the BSI journals-sponsored Poster Prizes! 🎉

Flavio Beke, Aisling Newing & Rébecca Barascud delivered outstanding research.👏

Full details here 👉 https://bit.ly/3MljD6r

Attending #BSI25?📣 Don’t miss AI in Publishing with Rachel Moriarty from our publisher OUP.

Explore how AI is shaping journals, research integrity & ethical practice, plus tips for using AI responsibly as an author.

🗓 3 Dec 2025 | ⏰ 13:15–14:10 | 📍 Hall 1C

#Immunology

Read 'Knowledge-based immune-therapeutic advances for transplantation and cancer' by Elizabeth Simpson here: doi.org/10.1093/imma...

Congratulations Liz! Read her historical perspective article in @imtadvances.bsky.social

Special Collection: CD40 turns 40: Four Decades of “Forty”-fying Immunotherapy

Since 1986, CD40’s role in #immunity has expanded. @imtadvances.bsky.social's upcoming collection will explore therapeutic targeting of CD40/CD154.

Submit your work to get involved: oxford.ly/3M5mYqo

#ImmunoSky #Immunotherapy

🛡️ This #PublishingIntegrityWeek, BSI journals are tackling papermills, promoting AI transparency, DEI & accessibility, and supporting ethical research in immunology.

Read more 👉 https://bit.ly/4odyvAZ

New review by Blee et al. “Turning the Tide: Harnessing Vaccines & Viruses to Fight Cancer” 🚀

How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk

#CancerResearch #Immunotherapy

🧬 Therapeutic cancer vaccines are back in focus! Advances in neo-antigen T cells, dendritic cell biology, and mRNA tech are paving the way for next-gen immunotherapy.

Read the Open Access review: https://bit.ly/4cefxGm

#CancerVaccines #Immunotherapy #mRNA #Oncology